Terminated PHASE1/PHASE2 INTERVENTIONAL NCT00259363

Oxaliplatin in Rectal Cancer

Phase I-II Study of Preoperative Oxaliplatin-FU and Radiotherapy for Patients With Rectal Cancer

Sponsor: Sanofi

Interventions Oxaliplatin

Updated 5 times since 2017 Last updated: Dec 4, 2009 Started: Oct 31, 2002 Primary completion: Jun 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study cancelled because recruitment rate was too slow

Other terminated trials from Sanofi

See all terminations from Sanofi

Other Rectal Neoplasms trials with similar outcome

Browse all Rectal Neoplasms trials

A PHASE1/PHASE2 clinical study on Rectal Neoplasms, this trial is terminated or withdrawn. The trial is conducted by Sanofi and has accumulated 5 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1_PHASE2

First recorded

Oct 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain